Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Erika Hamilton, MD, provides perspective on the latest immunotherapy treatment trends in TNBC

Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, provides perspective on the latest immunotherapy treatment trends in triple-negative breast cancer (TNBC)

Tags: BreastSABCS Conference Coverage

Published: 16 December 2020

Recent Videos: SABCS Conference Coverage

video

Kevin Kalinsky, MD, summarizes recent clinical data regarding the role of CDK 4/6 inhibitors

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, summarizes some recent clinical data regarding CDK 4/6 ...

video

Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares thoughts on the DESTINY-Breast01 clinical trial investigating ...

video

Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, considers the role of circulating tumor cells (CTCs) ...

video

Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares what the hematologist/oncologist community should know regarding ...

video

Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, offers opinion on whether results from the RxPONDER ...

video

Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020

Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares impressions of the RxPONDER clinical trial presented ...

video

Priya Rastogi, MD, on key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors

Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares key ...

video

Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020

Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, elaborates ...

video

Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchE

Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares thoughts ...

video

Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy

Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, discusses ...

Related Videos

video-image

Kevin Kalinsky, MD, summarizes recent clinical data regarding the role of CDK 4/6 inhibitors

video-image

Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020

video-image

Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer

video-image

Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer

video-image

Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER

video-image

Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020

video-image

Priya Rastogi, MD, on key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors

video-image

Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020

video-image

Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchE

video-image

Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy

video-image

Priya Rastogi, MD, considers the interchangeability of CDK 4/6 inhibitors

video-image

Adam Brufsky, MD, PhD, describes the treatment landscape of HER2+ metastatic breast cancer

video-image

Priya Rastogi, MD, elaborates on the role of abemaciclib in HR+, HER2- node positive breast cancer

video-image

Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer

video-image

Priya Rastogi, MD, shares the design and outcomes of the monarchE clinical trial from SABCS 2020

video-image

Adam Brufsky, MD, PhD, discusses results from the Phase III NALA study presented at SABCS 2020

video-image

Hope Rugo, MD, provides perspective on the clinical progress of CDK 4/6 inhibitors in breast cancer

video-image

Hope Rugo, MD, examines data from the DESTINY-Breast01 clinical study presented at SABCS 2020

video-image

Hope Rugo, MD, offers key takeaways for physicians regarding KEYNOTE-355

video-image

Hope Rugo, MD, considers chemotherapy recommendations based on findings from KEYNOTE-355

video-image

Hope Rugo, MD, shares the design and outcomes of KEYNOTE-355 presented at SABCS 2020

video-image

Hope Rugo, MD, considers the incidence of TNBC and what makes this disease so difficult to treat

video-image

Erika Hamilton, MD, considers the role of NGS testing for breast cancer patients

video-image

Erika Hamilton, MD, regarding the use of CDK 4/6 inhibitors in clinical practice

video-image

Erika Hamilton, MD, on promising treatment options in the management of HER2+ advanced breast cancer

video-image

Erika Hamilton, MD, discusses findings from the MARIO-3 clinical trial presented at the 2020 SABCS

video-image

Debra Patt, MD, PhD, MBA, speculates on exciting data in TNBC coming out of SABCS 2020

video-image

Debra Patt, MD, PhD, MBA, summarizes data from the ExteNET trial presented at SABCS 2020

video-image

Debra Patt, MD, PhD, MBA, comments on findings from the KEYNOTE-355 trial

video-image

Debra Patt, MD, PhD, MBA, provides perspective on the latest immunotherapy treatment trends in TNBC

video-image

Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors

video-image

Julie Gralow, MD, offers opinion on immunotherapy treatment trends in the management of TNBC

video-image

Julie Gralow, MD, regarding the ITOMIC trial data from the 2020 San Antonio Breast Cancer Symposium

video-image

Julie Gralow, MD, elaborates on the issue of resistance to endocrine therapies

video-image

Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer Symposium

video-image

Julie Gralow, MD, provides details on the SWOG S0226 findings presented at SABCS 2020

video-image

Elizabeth Mittendorf, MD, PhD, discusses the outcomes of the IMpassion-031 study

video-image

Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials

video-image

Elizabeth Mittendorf, MD, PhD, considers key takeaways from the Impassion-131 presented at ESMO 2020

video-image

Elizabeth Mittendorf, MD, PhD, discusses the IMpassion-130 clinical trial presented at ESMO 2020

video-image

Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020

video-image

Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020

video-image

Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan

video-image

Erika Hamilton, MD, shares thoughts on tolerability in high risk early breast cancer patients

video-image

Erika Hamilton, MD, considers the comparison between the monarchE and PALLAS clinical trials

video-image

Erika Hamilton, MD, considers the significance of the MonarchE study & the use of abemaciclib

video-image

Erika Hamilton, MD, regarding the Phase III monarchE trial presented at ESMO 2020

video-image

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

video-image

Erika Hamilton, MD, on the standard of care for high-risk early HR+, HER2- breast cancer

video-image

Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin

video-image

Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials

video-image

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

video-image

Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients

video-image

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

video-image

Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment

video-image

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

video-image

Nancy Lin, MD, on impressions of the Phase 2 study done the by the Translational Breast Cancer Consortium

video-image

Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management

video-image

Nancy Lin, MD, discusses the standard of care when adjuvant treating HR+, HER2- early breast cancer

video-image

Nancy Lin, MD, provides perspective on the global Phase 3 PALLAS trial regarding early breast cancer

video-image

Nancy Lin, MD, considers whether the results of the HER2CLIMB study will become a new care standard

video-image

Nancy Lin, MD, on the design and outcomes of the HER2CLIMB study regarding metastatic breast cancer

video-image

Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling

video-image

Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk

video-image

Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling